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Abstract
Background: The role of the diffusible messenger nitric oxide (NO) in the regulation of pain
transmission is still a debate of matter, pro-nociceptive and/or anti-nociceptive. S-Nitrosylation, the
reversible post-translational modification of selective cysteine residues in proteins, has emerged as
an important mechanism by which NO acts as a signaling molecule. The occurrence of S-
nitrosylation in the spinal cord and its targets that may modulate pain transmission remain
unclarified. The "biotin-switch" method and matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry were employed for identifying S-nitrosylated proteins.
Results: Here we show that actin was a major protein S-nitrosylated in the spinal cord by the NO
donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP). Interestingly, actin was S-nitrosylated, more in
the S2 fraction than in the P2 fraction of the spinal homogenate. Treatment of PC12 cells with
SNAP caused rapid S-nitrosylation of actin and inhibited dopamine release from the cells. Just like
cytochalasin B, which depolymerizes actin, SNAP decreased the amount of filamentous actin
cytoskeleton just beneath the membrane. The inhibition of dopamine release was not attenuated
by inhibitors of soluble guanylyl cyclase and cGMP-dependent protein kinase.
Conclusion: The present study demonstrates that actin is a major S-nitrosylated protein in the
spinal cord and suggests that NO directly regulates neurotransmitter release by S-nitrosylation in
addition to the well-known phosphorylation by cGMP-dependent protein kinase.
Background
Nitric oxide (NO) is produced from L-arginine by 3 iso-
forms of NO synthase (NOS), i.e., neuronal NOS (NOS-
1), inducible NOS (NOS-2), and endothelial NOS (NOS-
3); and it plays important roles in a wide variety of physi-
ological and pathophysiological processes such as neuro-
transmission, regulation of vascular tone, and mediation
of immune responses [1,2]. The major intracellular recep-
tor for NO is a soluble guanylyl cyclase that catalyzes the
synthesis of cGMP. This intracellular signaling molecule
modulates the activity of many targets in the cells includ-
ing cGMP-dependent protein kinase (cGK), ion channels,
and phosphodiesterases. In the central nervous system,
NO is mainly produced by NOS-1 and has been impli-
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cated in synaptic plasticity including long-term potentia-
tion in the hippocampus and in pain transmission in the
spinal cord [3-5]. Many behavioral studies including ours
have demonstrated that NO contributes to the develop-
ment and maintenance of hyperalgesia and allodynia in
models of acute and chronic pain, which are relieved by
the blockade of the NO/cGMP/cGK signaling pathway in
the spinal cord [6-9]. A rapid release of citrulline, a marker
of NO synthesis, is observed in the spinal cord following
a subcutaneous injection of formalin and is associated
with a biphasic flinching behavior of the injected paw
[10]. On the other hand, spinally administered NO
donors cause a depression of ongoing impulse activity of
dorsal horn neurons [11]; and inhibition of spinal NOS
leads to increased neuronal activity in the dorsal horn
[12]. Furthermore, agents affecting NO and cGMP levels
show no effect [13] or dual effects on nociception depend-
ing on their concentrations [14,15]. Thus the involvement
of NO in pain is not consistent and is still a matter of
debate. Different from many conventional neurotrans-
mitters that are stored in synaptic vesicles and released by
exocytosis, the labile, free-radical mediator NO simply
diffuses from the nerve terminal into adjacent cells and
acts as anterograde and retrograde messengers at nocicep-
tive synapses in the spinal cord [3]. Therefore, the mecha-
nisms through which NO mediates its nociception and
pain transmission are not completely understood in the
spinal cord [16].
In addition to the NO/cGMP/cGK signaling pathway, S-
nitrosylation by NO, i.e., the covalent attachment of a -
NO group to a cysteine thiol, has emerged as an important
feature of NO signaling [17,18]. Through this reversible
post-translational modification, NO is able to regulate the
function of many target enzymes, ion channels, and struc-
tural proteins including cyclooxygenase-2 [19], soluble
guanylyl cyclase [20], NMDA receptors [21-23], actin
[17,24], and other pathogenic proteins [25,26]. Among
methods for studying protein S-nitrosylation, the biotin-
switch method has rapidly gained popularity because of
the ease with which it can detect individual S-nitrosylated
proteins in biological samples [17,27]; and the use of this
method has revealed that S-nitrosylation is involved in
the physiology and pathophysiology of the central nerv-
ous system [18]. Although the NO/cGMP/cGK signaling
pathway has been extensively examined in terms of the
involvement of NO in nociception and pain transmission,
S-nitrosylation has not been studied in the spinal cord so
far. Here, by using the biotin-switch method, we demon-
strate that actin is a major S-nitrosylated protein in the
spinal cord by the NO donor S-nitroso-N-acetyl-DL-peni-
cillamine (SNAP) and that interestingly, actin was S-
nitrosylated, more in the S2 fraction than in the P2 frac-
tion of the spinal homogenate.
Methods
Materials
SNAP, nerve growth factor (NGF), 1H-[1,2,4]oxadiazolo-
[4,3-a]quinoxalin-1-one (ODQ) and KT5823 were
obtained from Wako Pure Chemical (Osaka, Japan). Trif-
luoroacetic acid (TFA), S-methyl methanethiosulfonate
(MMTS),  α-cyano-4-hydroxycinnamic acid (α-CHCA),
bovine serum albumin (BSA), imipramine hydrochloride,
dopamine, 8-bromoadenosine 3', 5'-cyclic monophos-
phate (8-Br-cAMP), 8-Br-cGMP, and glibenclamide were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Pitu-
itary adenylate cyclase-activating polypeptide (PACAP)
and  N-[6-(biotinamido)hexyl]-3'-(2'-pyridyldithio)pro-
pionamide (biotin-HPDP) were supplied by Peptide Insti-
tute (Osaka, Japan) and Pierce Chemical (Rockford, IL,
USA), respectively. Other chemicals were of reagent grade.
Preparation of S2 and P2 fractions from spinal cords
Male ddy mice (5 weeks old) were purchased from Shi-
zuoka Laboratory Centre (Hamamatsu, Japan). The mice
were housed under conditions of a 12-h light-12-h dark
cycle, a constant temperature of 22 ± 2°C, and 60 ± 10%
humidity. They received food and water ad libitum. All ani-
mal experiments were carried out in accordance with the
National Institutes of Health guide for the care and use of
laboratory animals and were approved by the Animal
Experimentation Committee of Kansai Medical Univer-
sity.
Under anesthesia with pentobarbital (50 mg/kg), mouse
spinal cords were quickly removed and homogenized
twice for 30 s with a Polytron homogenizer containing 10
volumes of HEN buffer consisting of 250 mM HEPES (pH
7.7), 1 mM EDTA, and 0.1 mM neocuproine. The
homogenate was centrifuged at 800 × g for 10 min, and
the supernatant was recovered and then centrifuged at
10,000 × g for 20 min. After the resulting pellet had been
dissolved in 10 volumes of HEN buffer, the resulting
supernatant and this dissolved pellet were employed as S2
and P2 fractions, respectively.
S-Nitrosylation of proteins in vitro and biotin-switch 
method
S-Nitrosylated proteins were detected by the biotin-switch
method as described by Jaffrey et al. [17]. Briefly, S2 and
P2 fractions of the spinal cord were incubated at room
temperature without or with various concentrations of
SNAP for 1 h in the dark. Then, SNAP was removed from
the reaction mixture by cold acetone precipitation; and
the pellets were subsequently dissolved in HENS buffer
containing 25 mM HEPES, pH 7.7, 0.1 mM EDTA, 0.01
mM neocuproine, and 1% sodium dodecyl sulfate (SDS).
The SNAP-treated fractions were blocked with fresh 4 mM
MMTS for 20 min at 50°C. After 2 steps of acetone precip-
itation, the pellets were then resuspended in HENS buffer.Molecular Pain 2009, 5:58 http://www.molecularpain.com/content/5/1/58
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For labeling, the samples were subjected to the biotin-
switch assay, in which the sample was mixed with 1 mM
ascorbic acid and 0.2-0.4 mM biotin-HPDP as final con-
centrations and kept for 1 h in the dark. Biotinylated pro-
teins were resolved by non-reducing SDS-polyacrylamide
gel electrophoresis (PAGE), and transferred to a polyvi-
nylidene difluoride membrane, followed by immunob-
lotting with peroxidase-conjugated anti-biotin antibody
(1:1000; Sigma-Aldrich). To confirm and quantify S-
nitrosylated actin in the S2 fraction of the spinal cord or
cell lysates, after the S-nitrosylated proteins had been
immunoblotted with anti-biotin antibody, the same
membrane was stripped to detect total actin with anti-
actin antibody (1:5000; BD Bioscience, San Jose, CA,
USA) by using Enhanced Chemiluminescence (GE
Healthcare, Piscataway, NJ, USA). The intensity of S-
nitrosylated actin was quantified by using ImageJ software
and normalized by that of total actin.
Furthermore, to detect individual S-nitrosylated proteins
including actin in S2 fractions of the spinal cord, we
removed free biotin-HPDP by using an NAP-5 column
(GE Healthcare) after the biotin-switch assay and incu-
bated the eluate overnight at 4°C with 50 μl of a strepta-
vidin-agarose slurry in 2 volumes of a neutralization
buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM
ETDA, and 0.5% Triton X-100). The beads were washed 4
times with 1 ml of the neutralization buffer supplemented
with 500 mM NaCl. The adsorbed proteins were eluted
with SDS-sample buffer at room temperature for 20 min.
The eluted sample was then analyzed by SDS-PAGE, fol-
lowed by immunoblotting with anti-actin antibody
(1:5000).
Identification of S-nitrosylated proteins by mass 
spectrometry
Most of the sample eluted from streptavidin-agarose gels
was applied to a 10% gel for SDS-PAGE and used for iden-
tification of S-nitrosylated proteins. After the gel had been
stained by the Vorum silver staining protocol [28], pro-
teins of interest were excised from the gel, destained, and
in-gel digested as described by Katano et al. [29]. The gel
piece was dehydrated with acetonitrile and dried by using
a Tomy CC-180 vacuum centrifuge concentrator (Tokyo,
Japan). After reduction with 10 mM dithiothreitol and
alkylation with 55 mM iodoacetamide, proteins in the gel
were digested overnight at 37°C with 10 μg/ml trypsin
(Promega, Madison, WI, USA) in 25 mM NH4HCO3. The
digested peptides were extracted with 50% acetonitrile in
1% TFA. Peptides were desalted and concentrated by
using a Ziptip μC18 (Millipore, Billerica, MA, USA) and
eluted with the matrix solution (1 mg/ml α-CHCA in 70%
acetonitrile and 1% TFA) onto a target plate. Matrix-
assisted laser desorption/ionization reflection time-of-
flight mass spectrometry (MALDI-TOF MS) was per-
formed by using a Voyager DE-PRO (Applied Biosystems).
All spectra were obtained in a positive reflector mode
using an accelerating voltage of 20 kV. Database searches
were carried out by using the MASCOT search program
http://www.matrixscience.com and NCBI protein data-
bases. The specified taxonomy was Mus musculus (house
mouse), and the specified initial mass tolerance was 50 or
70 ppm.
Cell culture and S-nitrosylation in cells
Pheochromocytoma cell line PC12 cells were maintained
in Dulbecco's modified Eagle medium supplemented
with 5% fetal calf serum, 10% horse serum, and 50 U/ml
penicillin and kept in a humidified environment of 95%
air and 5% CO2 at 37°C. For the S-nitrosylation assay, PC
12 cells were cultured on 6-cm dishes for 2 d; and the
medium was replaced with serum-free medium 12 h prior
to experiments. After 5-min treatment of the cells with
PACAP (10 nM) and/or SNAP (100, 300, 500 μM), the
cells were disrupted in HEN buffer by sonication; and the
lysate was then subjected to the biotin-switch assay.
Measurement of dopamine release from PC12 cells
PC12 cells were seeded on 24-well plates. After 2 days in
culture, the cells were preincubated for 15 min in 190 μl
of HEPES buffer (140 mM NaCl, 5 mM KCl, 2 mM CaCl2,
1.2 mM MgCl2, 10 mM glucose, and 10 mM HEPES, pH
7.4); and then the appropriate agents (10 μl) were added
to the medium. Incubation was carried out 37°C for the
desired times in the absence or presence of 10 μM imi-
pramine, an inhibitor of dopamine reuptake. After incu-
bation, the culture medium in each well was harvested;
and perchloric acid in HEPES buffer was then added to
each well for a final concentration of 3%. Culture media
and cell lysates were adjusted to pH 4 by 1 M sodium ace-
tate, and then the samples were centrifuged at 15,000 × g
for 5 min. The supernatants of culture media and cell
lysates were measured for dopamine released into the
medium and cellular dopamine by using an HPLC col-
umn equipped with an Eicom electrochemical detector
model 700 (Kyoto, Japan). HPLC was performed by using
a reversed-phase C18 column (Eicom CA-50DS, 2.1 mm
× 150 mm) with a phosphate-buffered mobile phase con-
taining 20% methanol, 50 mg/L EDTA, and 0.5 mg/L
sodium 1-octanesulfonate. Cellular dopamine content
was around 7.2 ± 0.8 ng/well; and basal and PACAP-
evoked release of dopamine into the culture media were
1.5-2 and 15-20% of cellular dopamine, respectively.
Immunoblot
Cerebellum and dorsal root ganglia (DRG) of mice and
PC12 cells were homogenized in 20 mM Tris-HCl (pH
7.4) containing 150 mM NaCl, 4 mM EDTA, 0.5 mM phe-
nylmethylsulfonyl fluoride, 1 μg/ml pepstatin A, 2 μg/ml
aprotinin, and 2 μg/ml leupeptin; and the supernatants
(100 μg) obtained after centrifugation at 10,000 × g for 30
min were subjected to immunoblotting on a polyvinyli-Molecular Pain 2009, 5:58 http://www.molecularpain.com/content/5/1/58
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dene difluoride membrane. After blocking with 5% (w/v)
BSA in TBS-T buffer at room temperature for 1 h, the
membrane was incubated overnight at 4°C with rabbit
anti-cGKI (type I cGK) antibody (1:200; Santa Cruz Bio-
tech., Santa Cruz, CA, USA) and then at room temperature
for 1 h with horseradish peroxidase-conjugated anti-rab-
bit-IgG (1:20,000; GE Healthcare). The immunoreactivity
was detected by using Enhanced Chemiluminescence.
Fluorescence images for actin in PC12 cells
PC12 cells (3 × 104 cells/well) were plated on poly-L-
lysine-coated glass-bottomed dishes (35 mm) and caused
to differentiate with NGF (50 ng/ml) in Dulbecco's mod-
ified Eagle medium supplemented with 1% fetal calf
serum and 2% horse serum for 4 days. After the cells had
been cultured overnight in serum-free medium, they were
incubated without or with SNAP (10, 30, 100 μM) or cyto-
chalasin B (10 μM) for 5 min. After fixation in 4% para-
formaldehyde in 0.12 M sodium phosphate buffer, pH
7.4 for 10 min, incubation with 0.3% Triton X-100 in
phosphate-buffered saline (PBS) for 15 min, 3 washings
with PBS, and blocking with 2% normal goat serum and
1% BSA in PBS for 30 min, the PC12 cells were stained for
actin. For this procedure, the cells were incubated for 2 h
at room temperature with Alexafluora 488-phalloidin
(1:500, Invitrogen, Eugeme, OR, USA) alone or with anti-
actin monoclonal antibody (1:800), and then for 1 h with
anti-mouse IgG-Alexafluora 546 antibody (1:500) in PBS.
Digital images were captured by a Zeiss LSM510 laser-
scanning confocal microscope (Oberkochen, Germany),
and the fluorescence intensity was quantified by using
ImageJ. More than 40 cells were quantified at each datum
point, and 3 experiments were carried out for each analy-
sis.
Statistics
Data were presented as the mean ± SD or mean ± SEM.
Data for dopamine release and S-nitrosylation of actin
were analyzed by paired Student's t-test and Mann-Whit-
ney U-test, respectively. Data for F-actin level were ana-
lyzed by one-way ANOVA and statistical significance was
further examined by Dunnett's test using a Statview soft-
ware program. P < 0.05 was considered significant.
Results
Identification of S-nitrosylated proteins with SNAP in the 
spinal cord
To identify S-nitrosylated proteins in the spinal cord, we
separated homogenates of the spinal cord into superna-
tant (S2) and pellet (P2) fractions after a 20-min centrifu-
gation at 10,000 × g. They were then incubated for 1 h
with various concentrations of SNAP, an NO donor, and
subjected to the biotin-switch assay for S-nitrosylation. As
shown in Figure 1A, S-nitrosylated proteins were detected
with anti-biotin antibody in both S2 and P2 fractions in a
concentration-dependent manner; and the extent of S-
nitrosylation in the S2 fraction was much higher than that
in the P2 fraction at 10 and 100 μM SNAP. Next, bioti-
nylated proteins in the S2 fraction treated with 100 μM
SNAP were purified on a streptavidin-agarose gel and
selectively eluted by using SDS-sample buffer containing
2-mercaptoethanol. Three major bands appeared after
SDS-PAGE (Figure 1B) and were in-gel digested and then
subjected to MALDI-TOF MS. The mass data were proc-
essed to assign candidate peptides in the NCBI database
by using the MASCOT search program. These three major
bands were identified as β-tubulin, β- and γ-actin, and
glyceraldehyde-3-phosphate dehydrogenase (Table 1).
Figure 1C shows the mass spectrum corresponding to
tryptic digests of actin. The sequence coverage of γ-actin
was 39%, and the probability-based MOWSE score was
130 with 12 matched peptides. Since the amino acid
sequences are highly conserved between β- and γ-actin,
these tryptic peptides did not discriminate them except for
the N-terminal portion (Figure 1D).
To confirm that S-nitrosylated protein identified by
MALDI-TOF MS was indeed actin, we immunoblotted the
eluate from the streptavidin-agarose gel with anti-actin
antibody. S-nitrosylated actin was detected in the eluate of
the S2 fraction treated with 100 μM SNAP (Figure 1E,
upper panel). Interestingly, however, it was not found in
the P2 fraction (Figure 1E, lower panel), suggesting that S-
nitrosylation was affected by the state of actin.
Effect of SNAP on dopamine release from PC12 cells
Acting as a cell-permeable intercellular messenger, NO is
known to affect neurotransmitter release. PC12 cells are a
rat pheochromocytoma cell line that endogenously pro-
duces dopamine and shares similar mechanisms of exocy-
tosis with neurons [30]. Dopamine is the predominant
catecholamine in PC12 cells [31], and PACAP is known to
stimulate the release of dopamine from PC12 cells. To
study whether SNAP affected the release of dopamine
from PC12 cells, we first examined the release elicited by
PACAP by using an HPLC column equipped with an elec-
trochemical detector. The basal release of dopamine into
the medium represented about 1.5-2% of the total cellular
dopamine in PC12 cells. Exposure to PACAP for 5 min
stimulated the release of dopamine in a concentration-
dependent manner, with an EC50 value of 2.42 nM; and
the release started to increase at 1 nM and reached the
maximum at 10 nM, at which concentration 15-20% of
the total cellular dopamine was released (Figure 2A).
When PC12 cells were treated with 10 nM PACAP, the
release reached the maximum at 5-10 min and gradually
decreased for 60 min (Figure 2B). In the presence of 10
μM imipramine, an inhibitor of dopamine reuptake, 10
nM PACAP stimulated the release for 60 min in a time-
dependent manner, suggesting that dopamine releasedMolecular Pain 2009, 5:58 http://www.molecularpain.com/content/5/1/58
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into the medium was reuptaken for a longer incubation.
When the effect of SNAP on dopamine release stimulated
by 10 nM PACAP was examined in the presence of imi-
pramine, 100 μM SNAP inhibited PACAP-induced
dopamine release from PC12 cells by 47.6, 30.4, 30.5, and
13.2% at 0.5, 5, 10, and 15 min after stimulation, respec-
tively (Figure 2C). Since the inhibitory effect decreased
with time, the effect of 100 μM SNAP on PACAP-evoked
dopamine release was examined at 5 min in the absence
of imipramine in subsequent experiments.
No involvement of NO/cGMP/cGK signaling pathway in 
the inhibitory effect of SNAP on dopamine release
In addition to recent findings of S-nitrosylation of
cysteine residues of specific proteins, NO has long been
known to bind to soluble guanylyl cyclase, leading to
Identification of protein S-nitrosylated by SNAP in the spinal cord as actin Figure 1
Identification of protein S-nitrosylated by SNAP in the spinal cord as actin. A. S2 and P2 fractions of mouse spinal 
cords were incubated with the indicated concentrations of SNAP for 1 h and subjected to the biotin-switch assay for S-
nitrosylation of proteins. Samples (5 μg of each) were resolved by non-reducing SDS-PAGE and immunobloted with anti-biotin 
antibody. B. The S2 fraction was incubated with 100 μM SNAP for 1 h and subjected to the biotin-switch assay. The bioti-
nylated proteins were purified by using a streptavidin-agarose gel, and the bound proteins were eluted by SDS-sample buffer 
containing 2-mercaptoethanol. Eluates were analyzed by SDS-PAGE, and proteins were visualized by silver staining. Three 
major bands were identified as β-tubulin, β- and γ-actin, and glyceraldehyde-3-phosphate dehydorogenase (GAPDH). C. 
MALDI-TOF MS spectrum used for identification of actin. Twelve matched mass peaks are indicated. D. Amino acid sequence 
of mouse γ-actin. The parts of the sequence in red correspond to the peptide fragments obtained by tryptic digestion. The 
amino acid sequence of β-actin completely matches residues 20-351 of γ-actin except that P at the 31st residue of γ-actin was 
replaced by S at the 12th residue of β-actin. E. S-Nitrosylation of actin by SNAP in the S2 fraction, but not in the P2 fraction, of 
the spinal cord. S2 and P2 fractions of spinal cords were incubated with 100 μM SNAP for 1 h and subjected to the biotin-
switch assay. After removing free biotin-HPDP, S-nitrosylated proteins were purified on streptavidin-agarose gels. Eluates were 
immunoblotted with anti-actin antibody as described in "Methods."
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Table 1: Proteins identified by MALDI-TOF MS
No Identified protein Mr (Da) % cover Pept matched Mowse score NCBI GI number
1 β-tubulin 50,281 27 12 96 4507729
2 γ-actin 41,340 39 12 130 809561
β-actin 39,451 39 12 131 49868
3 GAPDHa) 31,120 35 7 82 1.5E+08
a)GAPDH = glyceraldehyde-3-phosphate dehydorogenase.
Inhibition of PACAP-stimulated dopamine release from PC 12 cells by SNAP Figure 2
Inhibition of PACAP-stimulated dopamine release from PC 12 cells by SNAP. A. Concentration dependency of 
PACAP for dopamine release from PC12 cells. PC12 cells (4 × 105 cells/well) cultured on 24-well dishes were stimulated with 
various concentrations of PACAP for 5 min. B. Time courses of dopamine release from PC12 cells by PACAP. PC12 cells were 
stimulated for the indicated times with 10 nM PACAP in the absence (closed circles) or presence (open circles) of 10 μM imi-
pramine, an inhibitor of catecholamine reuptake. C. Inhibition of PACAP-stimulated dopamine release by SNAP. PC12 cells 
were stimulated with 10 nM PACAP without (open columns) or with (closed columns) 100 μM SNAP in the presence of 10 μM 
imipramine for the indicated times. Dopamine released into the medium and cellular dopamine were measured by HPLC as 
described in "Methods." Dopamine (DA) release (mean ± SD, n = 3) was expressed as a percentage of total dopamine (7.2 ± 
0.8 ng/well) in PC12 cells. *P < 0.05; **P < 0.01 vs. without SNAP.
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cGMP production and cGK activation. To clarify whether
the suppressive effect of SNAP on the dopamine release
was mediated by the NO/cGMP/cGK signaling pathway,
we examined whether the suppressive effect by SNAP
could be attenuated by ODQ, a guanylyl cyclase blocker;
KT5823, an inhibitor of cGK; or glibenclamide, an ATP-
sensitive K+ channel blocker [32]. When the suppressive
effect of SNAP was assessed at 5 min in the absence of imi-
pramine, ODQ (300 nM), KT5823 (1 μM) or glibencla-
mide (1 μM) affected neither the enhancement of
dopamine release by PACAP nor the suppression of the
release by SNAP (Figure 3A). To further examine whether
cGMP could mimic the inhibitory effect by SNAP, we
applied 100 μM 8-Br-cGMP and 8-Br-cAMP, permeable
analogs of cGMP and cAMP, respectively, to the cells
instead of SNAP. Different from SNAP, 8-Br-cGMP and 8-
Br-cAMP did not affect the dopamine release evoked by
PACAP (Figure 3B), demonstrating that the attenuation of
PACAP-enhanced dopamine release by SNAP was inde-
pendent of the NO/cGMP/cGK signaling pathway in
PC12 cells.
To further clarify that the suppressive effect by SNAP was
not mediated by cGK, we examined the expression of cGK
in PC12 cells by immunoblotting with anti-cGKI anti-
body. While it was detected in lysates of the cerebellum
and DRG, cGKI was not detected in PC12 cells (Figure
3C).
Inhibition of formation of filamentous actin (F-actin) by 
SNAP
To clarify the involvement of S-nitrosylation of actin in
dopamine release, we next examined whether actin was S-
nitrosylated with SNAP in PC12 cells. In PC12 cells, actin
was S-nitrosylated by SNAP in a similar manner, regard-
less of the presence of 10 nM PACAP (Figure 4A and 4B).
When the band intensity of S-nitrosylated actin was nor-
malized to that of total actin and the ratio without SNAP
treatment was taken as 1, S-nitrosylation of actin in PC12
No mediation of the cGMP/cGK pathway in inhibition of dopamine release by SNAP Figure 3
No mediation of the cGMP/cGK pathway in inhibition of dopamine release by SNAP. A. Effect of inhibitors of the 
NO/cGMP/cGK pathway on attenuation of dopamine release by SNAP. PC12 cells (4 × 105 cells/well) were stimulated for 5 
min with 10 nM PACAP without (open columns) or with (closed columns) 100 μM SNAP in the presence of 300 nM ODQ, 1 
μM KT5823 or 1 μM glibenclamide. B. Effect of cGMP and cAMP on dopamine release stimulated by PACAP. PC12 cells were 
stimulated for 5 min with 10 nM PACAP in the presence of 100 μM SNAP, 100 μM 8-Br-cGMP or 100 μM 8-Br-cAMP. 
Dopamine was measured by HPLC, and dopamine (DA) released into the medium (mean ± SD, n = 3) was expressed as a per-
centage of total dopamine in PC12 cells as described in the legend for Figure 2. *P < 0.05; **P < 0.01 vs. PACAP alone. C. 
Expression of cGKI in tissues and PC12 cells. Aliquots (100 μg/lane) of supernatants after centrifugation of homogenates of tis-
sues and PC12 cells at 10,000 × g for 30 min were applied to 7.5% SDS-PAGE and immunoblotted with anti-cGKI antibody.
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cells rapidly increased 1.93 to 3.11-fold and 1.69 to 3.29-
fold during a 5-min incubation in a concentration-
dependent manner from 100 to 500 μM SNAP in the
absence and presence of PACAP, respectively (Figure 4C).
It was hard to detect the increase in S-nitrosylated actin
above the control at less than 100 μM SNAP by the biotin-
switch assay (data not shown).
S-Nitrosylation of actin by SNAP was detected in the S2
fraction, but not in the P2 fraction of the spinal cord (Fig-
ure 1E). To get more insight into the relationship between
S-nitrosylation of actin and attenuation of dopamine
release by SNAP, we examined the alteration of F-actin in
NGF-differentiated PC12 cells. After NGF-differentiated
PC12 cells had been treated for 5 min with SNAP (10, 30,
100 μM) or cytochalasin B, a drug that prevents the addi-
tion of monomers to F-actin [33], the cells were double-
labeled with phalloidin for F-actin and anti-actin anti-
body for total actin. As shown in Figure 5A, whereas actin
(red) was broadly observed in the cell, F-actin (green) was
mainly observed beneath the cell membrane and in neur-
ites. The distribution and fluorescence intensity of total
actin did not change significantly after the addition of
SNAP. When normalized to that of total actin, the fluores-
cence intensity of F-actin (>40 cells/measurement, n = 3)
was rapidly reduced to 81.2, 49.4 and 41.6% by 10, 30,
and 100 μM SNAP in a concentration-dependent manner
(Figure 5B). Similar results were obtained with the cells
treated with cytochalasin B, and the extent of the decrease
in F-actin (38.4%) caused by cytochalasin B was similar to
that by 100 μM SNAP.
Conversely, we examined whether cytochalasin B would
attenuate dopamine release triggered by PACAP. As
shown in Figure 5C, cytochalasin B attenuated the
dopamine release similarly as 100 μM SNAP, suggesting
that SNAP reduced the amount of dopamine release from
PC12 cells by breakdown of the F-actin cytoskeleton just
beneath the plasma membrane.
Discussion
Many studies including ours have demonstrated that acti-
vation of the NMDA subtype of glutamate receptors and
subsequent NO production are a fundamental event in
S-Nitrosylation of actin by SNAP in PC12 cells Figure 4
S-Nitrosylation of actin by SNAP in PC12 cells. A, B. S-Nitrosylation of actin in PC12 cells by SNAP in the absence (A) 
and presence (B) of PACAP. PC12 cells (7 × 105 cells/dish) cultured in 6-cm dishes were exposed to 100, 300 or 500 μM 
SNAP with 10 nM PACAP for 5 min. The cell lysates in HEN buffer were subjected to the biotin-switch assay and analyzed by 
SDS-PAGE as described in "Methods." C. Quantification of S-nitrosylated actin in PC12 cells. Intensity of bands was quantified 
by ImageJ, and the extent of S-nitrosylated actin was normalized to total actin. S-Nitrosylated actin by SNAP in the absence (A, 
open columns) and presence (B, closed columns) of PACAP is expressed as a ratio (mean ± SEM, n = 3) to that at 0 μM SNAP. 
*P < 0.05 vs.0 μM SNAP without PACAP; #P < 0.05 vs.0 μM SNAP with PACAP.
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neurotransmission and synaptic plasticity in pain trans-
mission in the spinal cord [3-5]. The classical NO signal-
ing pathway is mediated by the generation of cGMP to
regulate cGK. In the present study, by use of the biotin-
switch method we first demonstrated that proteins in the
homogenate of the mouse spinal cord were S-nitrosylated
by the NO donor SNAP in a concentration-dependent
manner. Interestingly, the extent of S-nitrosylation was
more prominent in the S2 fraction than in the P2 fraction
(Figure 1A). The biotinylated proteins in the S2 fraction
were purified by using a streptavidin-agarose gel (Figure
1B); and β- and γ-actin, β-tubulin, and glyceraldehyde-3-
phosphate dehydrogenase were identified by MALDI-TOF
MS (Figure 1C and 4D, Table 1). These proteins were ear-
lier shown to be S-nitrosylated in brain lysates [17]. There
are several reports showing the S-nitrosylation of actin in
vitro and in vivo and nitrosylated cysteine moieties in the
carboxyl terminal area of actin, a region that is important
for actin polymerization and for binding several proteins
that modify behavior of the molecule [24,34]. One of
these sites is identified as Cys374, and the nitrosylated G-
actin is found to polymerize less efficiently [34]. A
number of experiments involving deletions or mutations
of actin at the C-terminus have demonstrated the impor-
tance of this region for proper F-actin polymerization and
stability. For example, mutating Cys374 to Ser in chicken β-
cytoplasmic actin increases the critical concentration for
polymerization by more than 5-fold [35]. Also, removal
of either 2 or 3 of the C-terminal residues of actin results
in actin filaments with increased fragility and flexibility
[36,37]. In the present study we demonstrated by phalloi-
din binding that the content of F-actin was rapidly
reduced by SNAP in a dose-dependent manner as well as
by cytochalasin B, an agent that depolymerizes actin, but
that the content of total actin was not changed (Figure 5A
and 5B).
Dopamine release and S-nitrosylation of actin
PC12 cells are a rat pheochromocytoma cell line that syn-
thesizes dopamine endogenously and are a commonly
employed cellular model for investigating the neuro-
trophic effects of PACAP [38]. PC12 cells share a similar
mechanism of exocytosis with neurons [30], and the
mechanisms underlying the release of dopamine from
PC12 cells, including membrane depolarization and
increase in intracellular Ca2+, have been extensively inves-
tigated through reconstitution of PAC1 receptors for
PACAP in PC12 cells [39]. As shown in this study, PACAP
stimulated dopamine release from PC12 cells in a concen-
tration-dependent manner with an EC50 of 2.42 nM (Fig-
ure 2A). Dopamine was rapidly released within 1 min
after stimulation with PACAP, and reuptake of it into the
cells started by 10 min (Figure 2B). Although SNAP atten-
uated the evoked release at any time from 0.5 to 15 min,
the extent of the inhibitory effect by SNAP was reduced
during a longer incubation in the presence of imipramine
(Figure 2C). Therefore, to simplify the elucidation of the
action mechanisms of SNAP, we examined the effect of
SNAP on the release for the initial 5 min. NO has long
been considered to act largely through cGMP formed by
activation of soluble guanylyl cyclase and subsequent cGK
activation in the nervous system [5]. It was previously
shown that an ATP-sensitive K+ channel is a target of cGK
and that glibenclamide directly blocks both acute and per-
sistent hypernociception via opening of an ATP-sensitive
K+ channel [32]. The inhibition by SNAP was not attenu-
ated by ODQ, a soluble guanylyl cyclase inhibitor;
KT5823, a cGK inhibitor; or glibenclamide, an ATP-sensi-
tive K+ channel blocker (Figure 3A). Conversely, neither 8-
Br-cGMP nor 8-Br-cAMP itself affected the basal release
(data not shown) or PACAP-enhanced dopamine release
(Figure 3B). Consistent with the distribution of cGKIα in
the cerebellum and DRG [40], it was detected in the
homogenate of the cerebellum and DRG, but not in PC12
cells (Figure 3C). These results demonstrate that the
inhibitory effect by SNAP was not mediated by the NO/
cGMP/cGK pathway.
Actin rearrangement and dopamine release
At the nerve terminal, the majority of synaptic vesicles are
bound within a layer of F-actin beneath the plasma mem-
brane [41,42]. Upon neuronal stimulation, breakdown of
the actin cytoskeleton is required for vesicle movement to
the plasma membrane and subsequent neurotransmitter
release. Thus, the classical view of actin rearrangements in
most secretory cells has been based on the actin-physical-
barrier model, whereby local disassembly of the cortical
actin network permits secretory granules to gain access to
exocytotic sites at the plasma membrane. However, this
model has been questioned because actin polymerization
may also play an important active role in the final stages
of exocytosis [43]. An important mechanism underlying
exocytosis is the assembly of distinct pools of synaptic ves-
icles at release sites, where two pools of synaptic vesicles
have been identified, the readily releasable pool and the
reserve pool. The readily releasable pool, constituting
only a small fraction of the total vesicles, represents those
vesicles released during the fast phase of exocytosis [44].
These vesicles are docked at the plasma membrane and
released rapidly upon cell stimulation. SNAP also inhib-
ited the KCl-induced domapine release (Lu J, unpublished
observation) and cytochalasin B also inhibited the
dopamine release evoked by PACAP (Figure 5C). Taken
together with our findings that the extent of S-nitrosyla-
tion was higher in the S2 fraction than in the P2 fraction
(Figure 1A) and that the inhibitory effect of SNAP on
dopamine release was greater during the early phase (Fig-
ure 2C), the present study suggests that the reduction in F-
actin by S-nitrosylation resulted in inhibition ofMolecular Pain 2009, 5:58 http://www.molecularpain.com/content/5/1/58
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dopamine release, possibly from the readily releasable
pool.
Two mechanisms of NO action in the spinal cord
We and others have demonstrated that NO contributes to
the development and maintenance of hyperalgesia and
allodynia in models of acute and chronic pain, which are
prevented by blockade of the NO/cGMP/cGK signaling
pathway in the spinal cord [6-9]. cGKIα is expressed in
small- or medium-diameter neurons of the lumbar DRG,
the class of neurons involved in nociceptive processing
and in central nerve terminals of laminas I and II in the
spinal cord, but is not present in spinal neurons and white
matter tracks [40,45]. By contrast, NOS-1 is present in
only 1-2% of lumbar DRG neurons; but NOS-1-contain-
ing fibers and small interneurons are present in all layers
of the spinal cord, especially in lamina II. Therefore, NO
has been supposed to act as a retrograde messenger [3,40],
i.e., to diffuse back to the presynaptic terminals of primary
afferent fibers where it stimulates soluble guanylyl cyclase
resulting in the formation of cGMP. It may, in turn, acti-
vate cGK, resulting in further glutamate release and NOS-
1 activation. We previously demonstrated that NO serves
as a retrograde messenger in the spinal cord and stimu-
lates glutamate release from primary afferent terminals
through the NO/cGMP/cGK pathway by the use of NO
donors such as NOR3 and SNAP [46,47].
Inhibition of dopamine release by SNAP through F-actin breakdown Figure 5
Inhibition of dopamine release by SNAP through F-actin breakdown. A. Representative fluorescence images of F-
actin distribution in PC12 cells. After PC12 cells (3 × 104 cells/well) had been treated for 5 d with NGF (50 ng/ml), they were 
incubated for 5 min with various concentrations of SNAP or 10 μM cytochalasin B (CB). After fixation with 4% paraformalde-
hyde, the cells were labeled with Alexafluora 488-phalloidin (green) for F-actin and anti-actin monoclonal antibody/Alexafluora 
546-anti-mouse IgG (red) for total actin. Bar = 5 m. B. Effect of SNAP and cytochalasin B on F-actin formation. Fluorescence 
intensity of more than 40 cells/slide was quantified by ImageJ as described in "Methods." Data are the mean ± SEM of 3 inde-
pendent experiments. *P < 0.05, **P < 0.01 vs. 0 M SNAP. C. Effect of cytochalasin B on dopamine release stimulated by 
PACAP. PC12 cells were stimulated for 5 min with 10 nM PACAP without or with 10 M CB, and dopamine release was meas-
ured as described in the legend for Figure 2. **P < 0.01 vs. without CB.
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In the present study, we first demonstrated that actin in
the S2 fraction of the spinal cord was S-nitrosylated by
exogenous NO; and our data suggest that S-nitrosylation
attenuated dopamine release by decrease in F-actin con-
tent in PC12 cells. It could be deduced that glutamate
release can be affected by NO-induced S-nitrosylation of
actin in the spinal cord. In this connection, the NO donor
sodium nitroprusside inhibited ongoing impulse activity
in 49% of all spinal neurons in the laminas I and II and
activated only 28% of them [11]. Although the biphasic
effect of NO on neuronal activity was vaguely considered
to be the difference in experimental conditions under
which neuronal background activity was examined, it may
be simply interpreted that NO affected glutamate release
in both inhibitory and stimulatory manners by the bal-
ance of S-nitrosylation and cGMP/cGK pathway.
Conclusion
Unlike the other second messengers, NO has the potential
to induce opposing effects and previous studies suggest
that the NO/cGMP signaling cascade showed both pro-
and anti-nociceptive effects [16]. Although which types of
cells in the spinal cord are S-nitrosylated remains to be
clarified, the present study suggests that 2 signaling path-
ways of NO action exist and that the contribution of these
2 pathways is determined to a considerable extent by the
presence of cGK in cells. Two signaling pathways may
explain the discrepancy in pain behaviors and electro-
physiological responses to NO donors in the spinal cord.
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